医疗特长：从事恶性肿瘤的综合诊疗工作十余年，擅长胸腹常见恶性肿瘤（如乳腺癌、肺癌、肝癌、胃癌、结直肠癌等）的放化疗、靶向药物治疗、生物免疫治疗及微创介入治疗。一直从事恶性肿瘤的临床和基础研究工作，立足于国内工作，并积极开展国内外合作，与中山大学肿瘤医院及美国哈佛医学院BIDMC建立了深度合作关系，取得系列成绩。发表SCI学术论文60余篇，发表于JCO杂志的论文被评为2013年中国临床肿瘤研究十大进展之一，5项学术成果被国际权威指南引用并改变指南，获得包括国自然面上基金在内的5项基金的支持。2014年获得珠江科技新星称号，2017年获得中山大学附属第一医院柯麟新锐计划支持。主要教育和工作经历：09/2015-06/2017 中山大学附属第一医院 肿瘤学 博士09/2005-06/2008 中山大学肿瘤防治中心 肿瘤学 硕士09/2000-07/2005 华中科技大学同济医学院临床医学学士04/2013-03/2015 哈佛医学院 Beth Israel Deaconess Medical Center 博士后01/2013-至今 中山大学附属第一医院主治医师07/2011-12/2012 中山大学附属第一医院医师08/2008-06/2011 中山大学肿瘤防治中心医师社会兼职：广东省抗癌协会肝癌委员会青年委员会常委 广东省中西医结合学会肿瘤生物治疗委员会委员 广州市抗癌协会肝胆胰委员会委员论著（部分代表作）：1. Peng ZW, Chen SL, Wei MC, et al. Sorafenib with or without Transarterial Chemoembolization plus Radiofrequency Ablation for Advanced Recurrent Hepatocellular Carcinoma. Radiology, in press. IF: 7.2962. Peng ZW, Wei MC, Chen SL, et al. Combined Transcatheter Arterial Chemoembolization and Radiofrequency Ablation versus Hepatectomy for Recurrent Hepatocellular carcinoma after Initial Surgery: A Propensity Score Matching study. Euro Radiol, in press. IF: 3.9673. Chen SL, PengZW, Xiao H, et al. Combined Radiofrequency Ablation and Ethanol Injection Versus Repeat Hepatectomy for Elderly Patients with Recurrent Hepatocellular Carcinoma after Initial Hepatic Surgery. Int J Hyperthermia. 2017. Co-first author. IF: 3.2624. Peng ZW, Rothweiler S, Wei GY, et al. The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis. Hepatol commun. 2017;1:957-972.5. Peng ZW, Ikenaga N, Liu SB, et al. Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis. Hepatology; 2016;63:217-32.IF: 13.2466. Xu L, Peng ZW, Chen MS, et al. href="http://www.ncbi.nlm.nih.gov/pubmed/25725438">Prognostic Nomogram for Patients with Unresectable Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. J Hepatol 2015;63:122-30 Co-first author. IF: 12.4867. Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency Ablation with or without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. J Clin Oncol.2013;31;426-432.IF: 24.0088. Peng ZW, Zhang YJ, Chen MS et al. Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and Radiofrequency Ablation versus Radiofrequency Ablation Alone: A Prospective Randomized Trial. Radiology. 2012; 262:689-700. IF: 7.2969. Peng ZW, Zhang YJ, Lin XJ, et al. Radiofrequency ablation vs. hepatic resection for the treatment of hepatocellular carcinomas smaller than 2 cm: A retrospective comparative study. Radiology. 2012; 262:1022-1033. IF: 7.29610. Peng ZW, Liu FR, Ye S, et al. href="http://www.ncbi.nlm.nih.gov/pubmed/23922119">Radiofrequency ablation versus open hepatic resection for elderly patients (>65 years) with very early or early hepatocellular carcinoma. Cancer. 2013; 119:3812-3820. Co-corresponding author. IF: 5.997其他主要工作成绩（比如获奖情况）：1. 小肝癌综合治疗，广东省科技进步一等奖2. 小肝癌综合治疗，教育部科技进步二等奖；3. 小肝癌经皮射频微创治疗的临床研究(2009)，中国抗癌协会科技奖二等奖4. 2009年度中山大学肿瘤防治中心“邓先生抗癌科学奖”三等奖；2007年中山大学优秀研究生；